Loading data
MYONYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 40.93 m USD | 32.55 m USD | 19.24 m USD | 15.56 m USD | 13.86 m USD |
| Cost of revenue | 14.04 m USD | 9.37 m USD | 6.06 m USD | 5.3 m USD | 3.54 m USD |
| Gross profit | 26.89 m USD | 23.19 m USD | 13.18 m USD | 10.25 m USD | 10.31 m USD |
| Research and development expense | 6.94 m USD | 4.77 m USD | 2.64 m USD | 2.48 m USD | 2.56 m USD |
| Selling, general and administrative expense | — | — | 18.78 m USD | 18.44 m USD | 18.02 m USD |
| Operating profit | -14.4 m USD | -6.21 m USD | -8.23 m USD | -10.67 m USD | -10.27 m USD |
| Profit before tax | -15.07 m USD | -5.82 m USD | -7.99 m USD | -10.65 m USD | -10.28 m USD |
| Income tax expense | 504.53 k USD | 365.62 k USD | 156 k USD | 69.94 k USD | 88.93 k USD |
| Net income (reported basis) | -15.6 m USD | -6.2 m USD | -8.1 m USD | -10.7 m USD | -10.37 m USD |
| Net income attributable to common shareholders | — | — | — | -10.72 m USD | -11.01 m USD |
| Basic earnings per share | -0.37 USD/share | -0.16 USD/share | -0.28 USD/share | -1.52 USD/share | -1.89 USD/share |
| Diluted earnings per share | -0.37 USD/share | -0.16 USD/share | -0.28 USD/share | -1.52 USD/share | -1.89 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.